B-RAF is a serine/threonine-specific protein kinase that is mutated in approximately 70% of human melanomas. However, the role of this signalling molecule in cancer is unclear. Here, we show that ERK is constitutively activated in melanoma cells expressing oncogenic B-RAF and that this activity is required for proliferation. B-RAF depletion by siRNA blocks ERK activity, whereas A-RAF and C-RAF depletion do not affect ERK signalling. B-RAF depletion inhibits DNA synthesis and induces apoptosis in three melanoma cell lines and we show that the RAF inhibitor BAY43-9006 also blocks ERK activity, inhibits DNA synthesis and induces cell death in these cells. BAY43-9006 targets B-RAF signalling in vivo and induces a substantial growth delay in melanoma tumour xenografts. Our data demonstrate that oncogenic B-RAF activates ERK signalling, induces proliferation and protects cells from apoptosis, demonstrating that it is an important therapeutic target and thus provides novel strategies for clinical management of melanoma and other cancers.
To investigate the role of oncogenic B-RAF signalling in melanoma we first examined MEK-ERK signalling in melanoma cell lines that harbour activating mutations in the B-RAF gene. Three melanoma cell lines expressing oncogenic B-RAF (A375: Tuveson et al., 2003; Davies et al., 2002) have constitutively elevated ERK activity as shown by Western blotting with an antibody that only binds to the dually phosphorylated, active forms ( Figure 1a ). The MEK inhibitor U0126 blocked this constitutive ERK signalling ( Figure 1b ) and also blocked DNA synthesis in these cells ( Figure 1c ). In contrast, ERK was not constitutively activated in CHL cells (Figure 1a ), a melanoma cell line that expresses wild-type B-RAF , and U0126 did not block their ability to synthesize DNA ( Figure 1c ). The low levels of ERK activity in melanoma cells that express wild-type B-RAF compared to those that express oncogenic B-RAF is consistent with previous studies (Satyamoorthy et al., 2003) . These results demonstrate that melanoma cells harbouring oncogenic B-RAF have constitutively elevated ERK activity and that MEK-ERK signalling is required for their proliferation.
To examine B-RAF in more detail, we used RNA interference to deplete individual RAF isoforms. Under the experimental conditions used here, each small interfering RNA (siRNA) oligonucleotide was specific for its target protein. The A-RAF siRNA depleted A-RAF, but not B-RAF or C-RAF, the B-RAF siRNA only targeted B-RAF and the C-RAF siRNA only targeted C-RAF (Figure 1d ). Curiously, under some conditions we observed some loss in specificity with these reagents (data not shown) despite the fact that they were selected to be specific, so as an additional control, we used a nonspecific 'scrambled' oligonucleotide, which did not affect expression of any of the RAF isoforms (Figure 1d) . B-RAF depletion suppressed the constitutive ERK signalling in A375, Colo829 and WM-266-4 cells ( Figure 1d ) and as expected from the U0126 data, it also caused a block in DNA synthesis (Figure 1e ). Unfortunately, we have been unable to develop siRNA molecules that distinguish between the wild type and oncogenic B-RAF and the siRNA used here depletes both WT B-RAF and V599E B-RAF. Nevertheless, we have shown that ERK activity is only elevated in melanoma cells expressing activated B-RAF mutants, that B-RAF stimulates constitutive ERK signalling and that this is required for proliferation. Furthermore, B-RAF siRNA does not block ERK signalling in RAS transformed melanoma cells (Wellbrock et al, 2004) , demonstrating that wild-type B-RAF is not required for the growth of these cells. Together these data strongly suggest that oncogenic B-RAF Figure 1 Oncogenic B-RAF stimulates constitutive ERK signalling and proliferation in melanoma cells. (a) CHL, A375, Colo829 and WM-266-4 whole-cell lysates (30 mg) were prepared as previously described (Marais et al., 1997; Chiloeches et al., 2001) and Western blotted using an antiphospho-ERK (ppERK) monoclonal antibody (Sigma). (b) Western blot using anti-pp-ERK antibody of the indicated cell lines after 24 h treatment with BAY43-9006 (B; 10 mM) or UO126 (U; 10 mM). The same membrane was blotted with an anti-tubulin antibody (Sigma) as a loading control. (c) [ 3 H]thymidine incorporation in CHL, A375, Colo829 and WM-266-4 cells in the presence of DMSO or U0126 (10 mM) as previously described (Marais et al., 1996) . (d) Western blot showing expression levels of A-RAF (C-20; Santa Cruz), B-RAF (F-7; Santa Cruz), C-RAF (Transduction Labs), ppERK (Sigma) and total ERK (clone 122; (Leevers, 1993) ) in A375, Colo829 and WM-266-4 (72 h after siRNA) transfected with the indicated siRNA oligonucleotides (M: Mock; S: scrambled; A: A-RAF; B: B-RAF; C: C-RAF). Transfections with siRNA were performed as we previously described (Wellbrock et al., 2004) using the following siRNA sequences: A-RAF: AAC AAC ATC TTC CTA CAT GAG; B-RAF: AAA GAA TTG GAT CTG GAT CAT (Hingorani et al., 2003) ; C-RAF: AAU AGU UCA GCA GUU UGG CUA; Scrambled: AAA CCG UCG AUU UCA CCC GGG. (e) [ stimulates constitutive MEK-ERK signalling in melanoma cells and that this signalling is required for proliferation.
Unlike B-RAF, C-RAF and A-RAF depletion did not suppress ERK activity in the melanoma cell lines (Figure 1d ), but it still affected DNA synthesis ( Figure 1e ). In A375 cells, A-RAF and C-RAF siRNA both suppressed DNA synthesis by approximately 50%. In Colo829 cells, C-RAF siRNA was more efficient than A-RAF siRNA whereas in WM-266-4 cells, A-RAF siRNA was more efficient than C-RAF siRNA. In Colo829 cells, C-RAF siRNA was as efficient as B-RAF siRNA and in WM-266-4 cells, A-RAF siRNA was as efficient as B-RAF siRNA. Thus, in these cells, A-RAF and C-RAF are not required to signal to MEK and ERK under normal tissue culture conditions and they fail to compensate for B-RAF loss. However, we have recently shown that in RAS transformed melanoma cells, B-RAF depletion does not result in ERK inactivation or suppression of DNA synthesis (Wellbrock et al, 2004) , suggesting that A-RAF and/or C-RAF can compensate for B-RAF loss under some circumstances. Nevertheless, despite the fact that A-RAF and C-RAF do not appear to play a role in MEK-ERK signalling, they still contribute to the regulation of DNA synthesis in these cell lines. Possible explanations for this ERK-independent role are that these RAF isoforms act as scaffolds or participate in other signalling pathways. For example, C-RAF does possess activities that are independent of its kinase activity (Hu¨ser et al., 2001 ) and, thus, further studies are required to elucidate the role that C-RAF and A-RAF play in DNA synthesis in melanoma cells.
We next examined whether B-RAF played a role in cell survival by examining effects on the cell-cycle profiles of the cells. B-RAF depletion induced a significant increase in the sub-G1 population of all three cell lines after 96 h (Figure 2a ), induced caspase 3 activation ( Figure 2b ) and induced PARP cleavage (Figure 2c) . A-RAF depletion failed to induce any of these markers of apoptosis ( Figure 2 ) and although C-RAF induced a small increase in the sub-G1 population in Colo829 and WM-266-4 cells, it failed to stimulate efficient caspase 3 activation or PARP cleavage (Figure 2 ). Taken together, these data demonstrate that in addition to stimulating cell proliferation, B-RAF also provides a survival signal to these melanoma cell lines. While C-RAF also appears to play a role in maintaining cell viability, A-RAF does not seem to provide a survival signal.
A role for B-RAF in survival is consistent with previous studies. It has been shown that inhibition of MEK sensitized one out of four melanoma cell lines to cisplatin, an agent that induces apoptosis (Mandic et al., 2001 ) and mice that are null for B-raf die due to catastrophic endothelial cell apoptosis in utero (Wojnowski et al., 1997) . Furthermore, neuronal cells that are null for B-raf display increased apoptosis in the absence of nerve growth factor (Wiese et al., 2001) and WT B-RAF protects fibroblasts from apoptosis in the absence of growth factors, apparently by blocking caspase activation (Erhardt et al., 1999) . A role for C-RAF in survival is also consistent with previous studies (Mercer and Pritchard, 2003) . Haematopoetic cells and MEFs from C-raf null mice have increased rates of spontaneous apoptosis and are more sensitive to apoptotic signals (Hu¨ser et al., 2001; Mikula et al., 2001) . Furthermore, C-RAF antisense oligonucleotides induced apoptosis in several cancer cell lines (Lau et al., 1998) that are wild type for B-RAF . Our data demonstrate that in melanoma cells, B-RAF plays a major role in survival whereas C-RAF plays a lesser role. Furthermore, the C-RAF survival signal is ERK independent, which is consistent with our previous data demonstrating that in MEFs the C-RAF survival signal is independent of its kinase activity (Hu¨ser et al., 2001) . Future studies will focus on how B-RAF survival signals interact with other survival pathways in melanocytes. For example, the proapototic protein APAF-1 is downregulated in approximately 40% of melanomas (Soengas et al., 2001 ) and it will be interesting to compare B-RAF survival signals in cells where APAF-1 is or is not downregulated.
Our data establish that B-RAF is required for both growth and survival of melanoma cells in vitro, so we tested whether it is a therapeutic target in vivo. First we tested whether the C-RAF inhibitor BAY43-9006 (Lyons et al., 2001 ) was active against oncogenic B-RAF. BAY43-9006 blocked V599E B-RAF in vitro kinase activity with an IC 50 of B43 nM (Figure 3a) , so the compound is somewhat less active against V599E B-RAF than against activated wild-type C-RAF (IC 50 B6-12 nM; Lyons et al., 2001) . Nevertheless, BAY 43-9006 blocked the constitutive ERK activity in A375, Colo829 and WM-266-4 cells (Figure 1b) , and since our data demonstrate that ERK activity is dependent on B-RAF but not C-RAF or A-RAF (Figure 1d ), we conclude that BAY 43-9006 is able to block B-RAF activity in melanoma cells. BAY43-9006 also blocked DNA synthesis ( Figure 3b ) and induced death in all three lines (Figure 3c ). U0126 also induced death in all three cell lines (data not shown). We do note that BAY43-9006 is less active in cells than against V599E B-RAF in vitro, inhibiting the growth of A375, Colo829 and WM-266-4 cells at concentrations of 4-6.5 mM (Table 1) , possibly because the drug is not fully permeable to cells, or because of the high ATP concentrations inside cells. Nevertheless, since BAY43-9006 does target ERK signalling in cells, blocks proliferation and induces cell death, we tested its activity in vivo.
WM-266-4 cells were grown as human tumour xenografts in the flanks of nude mice and after 6 days when the tumours were palpable, the mice were orally dosed with 50 mg/kg BAY43-9006 or vehicle control once a day for 17 days. Tumour diameters were measured and their volumes were calculated. BAY43-9006 elicited a significant growth retardation (55% at 17 days of treatment: two-tailed Mann-Whitney test: Po0.05) compared to the vehicle treated controls (Figure 4a ). The tumours were excised on the last day of treatment and immuno-stained for active MEK, using an antibody that only binds to phosphorylated, active MEK1 and MEK2. There was a substantial reduction in MEK activity in tumours from the BAY43-9006 treated mice compared to the vehicle treated controls (Figure 4b ).
Our data show that oncogenic B-RAF stimulates constitutive ERK activity in melanoma cells, providing both proliferation and survival signals. These data are consistent with a recent study demonstrating similar results in WM793 melanoma cells (Hingorani et al., 2003) . Our study also shows that BAY43-9006 targets B-RAF in vitro and in vivo, and was able to elicit a significant retardation in the growth of human melanoma tumour xenografts. However, we were unable to produce complete cures of the animals, and further . Samples were fixed in 4% formaldehyde/PBS, washed 3 Â with PBS, permeabilized (0.2% Triton X-100 : PBS) and blocked (0.1% Triton X-100 : BSA : PBS) for 30 min at room temperature. Activated caspase 3 was detected using a polyclonal antibody recognizing caspase 3 cleaved at Asp 175 (9661S; Cell Signalling) followed by an anti-rabbit FITC secondary antibody (Jackson ImmunoResearch). (c) Western blots showing PARP expression in A375, Colo829 and WM-266-4 cells at 72 h after siRNA transfection using an anti-PARP monoclonal antibody (Pharmingen). The arrow indicates full-length PARP and the asterisk the cleavage product B-RAF is a therapeutic target in melanoma M Karasarides et al studies will aim to improve the schedulling of the drug. It is also possible that BAY43-9006 is simply not potent enough to elicit a response as a monotherapy and that better responses will be obtained if the drug is used in combination with more conventional anticancer agents.
BAY43-9006 and U0126 are clearly more potent than siRNA at blocking B-RAF signalling in melanoma cells. ERK was inhibited more efficiently (compare Figures  1b, d ) and more rapidly (data not shown) with BAY43-9006 than with B-RAF siRNA, and BAY43-9006 inhibited DNA synthesis more effectively and induced cell death more rapidly (Figures 1-3) . This is presumably because the loss of B-RAF protein through degradation occurs more slowly than its inhibition by a small molecular inhibitor. In addition, BAY43-9006 may target several kinases, the combination producing a more potent effect than targeting a single protein with siRNA. Furthermore, in vivo BAY43-9006 may directly target the tumour cells through B-RAF inhibition and produce an antiangiogenic effect by inhibiting C-RAF, which is downstream of the VEGF receptor and provides survival signals to endothelial cells (Alavi et al., 2003) . Finally, additional targets may also exist in the complex environment of the tumour that is not present in melanoma cells growing in tissue culture.
Our studies reveal an interesting parallel between BAY43-9006 and the small molecule Imatinib (STI571, Glivec). Imatinib is a potent inhibitor of Abl, a tyrosine cells were seeded in 96-well plates and cultured in 10% FBS. The next day the cells were treated with a range of concentrations of BAY43-9006 for 4-7 days and then fixed and stained with sulphorhodamine-B, and their absorbance was determined at 590 nm. The results are expressed as percentage of control growth as a function of log (dose) and the IC 50 determined by nonlinear regression, constraining the minimum to be positive (GraphPad Prism). Each experiment was performed in quadruplicate and repeated four times kinase that is hyper-activated in over 90% of chronic myeloid leukemia (CML) (Druker and Lydon, 2000) . Like BAY43-9006, Imatinib inhibits cell proliferation, stimulates apoptosis and sensitizes cells to DNAdamaging chemotherapeutic drugs. Thus, agents that block signalling pathways can kill cells rather than just block their proliferation and offer enormous therapeutic potential both as mono-therapies and in combination with conventional cancer drugs. Importantly, B-RAF targeted therapies may find utility in other cancers where the B-RAF gene is mutated, such as 30% of lowgrade ovarian cancers (Singer et al., 2003) , 35-70% of papillary thyroid cancers Kimura et al., 2003) and 10-15% of colorectal cancers Rajagopalan et al., 2002; Yuen et al., 2002) .
In conclusion, our data show that oncogenic B-RAF is an important therapeutic target in melanoma and that it offers novel strategies for the clinical management of many types of cancer.
